Weight-loss drug Ozempic to debut in India soon

Novo Nordisk will launch Ozempic in India. This injectable drug manages type 2 diabetes and aids weight loss. It enters a competitive market against Eli Lilly's Mounjaro. Novo Nordisk's Wegovy also competes. The company's semaglutide patent expires next year, allowing generic versions. India has a large population with diabetes and obesity. Ozempic offers significant health benefits.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZgRvDCk
via IFTTT